Avillion Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 45
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 2

Avillion General Information


Provider of drug development services intended to assist biotech organizations in their development and financing of later stage pharmaceutical products. The company's services facilitate the acceleration of global drug development through successful partnering for patient benefit by providing strategic development and regulatory expertise, funding, global CRO management and risk-sharing, enabling pharmaceutical and biotechnology companies to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves and advance late-stage clinical development projects through to market approval.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 4 Longwalk Road
  • Hayes, Stockley Park
  • Uxbridge UB11 1FE
  • England, United Kingdom
+44 020 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avillion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private Completed Generating Revenue
2. Early Stage VC 06-May-2014 Completed Generating Revenue
1. Early Stage VC 28-Jan-2013 Completed Generating Revenue
To view Avillion’s complete valuation and funding history, request access »

Avillion Executive Team (13)

Name Title Board Seat Contact Info
Allison Jeynes-Ellis MD Co-Founder & Chief Executive Officer
Mark Weinberg MD Chief Medical Officer & President
Mary Sheahan Chief Financial Officer
Laurence Reilly MD Chief Scientific Officer & Vice President
Anna Danilewicz Director of Clinical Development
You’re viewing 5 of 13 executive team members. Get the full list »

Avillion Board Members (8)

Name Representing Role Since
Anders Pedersen MD Self Board Member 000 0000
David Chiswell Ph.D Self Board Member 000 0000
Genghis Lloyd-Harris Ph.D Abingworth Management Board Member 000 0000
Jim Reddoch Ph.D Royalty Pharma Board Member 000 0000
Kurt Wheeler Blackstone Life Sciences Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Avillion Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avillion Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Royalty Pharma Corporation Minority 000 0000 000000 0
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
To view Avillion’s complete investors history, request access »